In Germany, the Race for the Vaccine Heats Up

04/25/2020 03:00 | NaN

In Germany, the Race for the Vaccine Heats Up

A major Chinese pharmaceutical company has invited a premier national health institute of Pakistan to collaborate in conducting clinical trials of its recently developed inactivated vaccine for COVID-19 in Pakistan, a media report said on Thursday.

It further said, "The NIH is requested to facilitate the approval of the Ministry of National Health Services and Regulatory Corporation and Drug Regulatory Authority of Pakistan (DRAP) for the clinical trial".

The Phase I/II clinical trials will, amongst other things, fundamentally test the tolerability and safety of the potential vaccine. We hope that we have succeeded by giving you the full details and information.

"We want to increase the trend of clinical trials in the country".

The World Health Organisation (WHO) said there are about 20 different potential COVID-19 vaccines now in development.

Yet while Biontech hailed what it called a "global development program" on Wednesday, the search for a vaccine has also been a cause of friction between countries.

These clinical trials will initially be carried out on 200 healthy volunteers aged from 18 to 55 years. Germany's CureVac and the USA biotech Moderna, have developed their messenger-RNA vaccines.

British Health Minister Matt Hancock announced that scientists at Oxford University will start testing a new vaccine on humans tomorrow. There are 150 vaccine projects now underway in the world, but Germany and the United Kingdom are among the five countries that have been allowed clinical trials.

The second part of the study will evaluate the candidates in patients who are at higher risk of a severe COVID-19 infection.

On 16 March, Beijing approved the first trial of a vaccine developed by the Academy of Military Medical Sciences, supported by the army, and the biotechnology company CanSino Bio, listed in Hong Kong.

Following the announcement of the coronavirus vaccine study approval, shares of Pfizer and BioNTech were up 1.8% and 26.6%, respectively, on April 22. To combat the pandemic, additional vaccine products will be necessary to ensure a sufficient supply of the vaccines.


Add comment